^
    1d
    IL-8-Induced Tumor Self-Rampart Spatially Confines Oncolytic Virotherapy in Glioblastoma. (PubMed, Neuro Oncol)
    Glioblastoma mounts a spatial self-protective defense through IL-8-driven TSR formation that restricts oncolytic virus spread. IL-8 functions as both a pharmacodynamic biomarker and a therapeutic target, and its inhibition provides a rational strategy to overcome resistance and optimize GBM virotherapy.
    Journal • IO biomarker
    |
    CXCL8 (Chemokine (C-X-C motif) ligand 8)
    |
    YSCH-01 • reparixin (DF 1681Y)
    11ms
    ADVANCE-GBM: Evaluating the efficacy of YSCH-01 oncolytic virus as a single agent and in combination with Atezolizumab for recurrent glioblastoma. (ChiCTR2400092993)
    P=N/A, N=10, Huashan Hospital, Fudan University; Huashan Hospital, Fudan University
    New trial
    |
    Tecentriq (atezolizumab) • YSCH-01
    over1year
    An open, single/multiple dose escalation and dose extension clinical study evaluating the safety/tolerability and initial efficacy of YSCH-01 intratumoral injection in subjects with advanced solid tumors (ChiCTR2400083915)
    P1, N=49, Recruiting, Affiliated Cancer Hospital of Shandong First Medical University; Shanghai Yuansong Biotechnology Co., LTD.
    New P1 trial
    |
    EGFR (Epidermal growth factor receptor) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • BRCA (Breast cancer early onset)
    |
    YSCH-01
    over1year
    Preliminary efficacy and safety of YSCH-01 in patients with advanced solid tumors: an investigator-initiated trial. (PubMed, J Immunother Cancer)
    The study shows that YSCH-01 injections were safe and well tolerated and exhibited preliminary efficacy in patients with advanced solid tumors, supporting further investigation to evaluate its efficacy and safety.
    Journal • Metastases
    |
    IFNG (Interferon, gamma) • IL6 (Interleukin 6)
    |
    YSCH-01
    2years
    Double-modified oncolytic adenovirus armed with a recombinant interferon-like gene enhanced abscopal effects against malignant glioma. (PubMed, Neurooncol Adv)
    Furthermore, we employed a patient-derived xenograft model of recurrent glioblastoma to test the effectiveness of YSCH-01 against temozolomide. Our initial findings confirm that a double-modified oncolytic adenovirus armed with a recombinant interferon-like gene is both safe and effective in the treatment of malignant glioma. Furthermore, when utilized in combination with a targeted therapy gene strategy, these oAds exhibit a more profound effect in tumor therapy and an enhanced ability to inhibit tumor growth at remote sites.
    Journal • Oncolytic virus
    |
    BIRC5 (Baculoviral IAP repeat containing 5)
    |
    temozolomide • YSCH-01
    over2years
    YSCH-01: Safety and Tolerability Study of Recombinant L-IFN Adenovirus Injection in Patients With Recurrent Glioblastoma (clinicaltrials.gov)
    P1, N=6, Recruiting, Binhai Hospital of Fujian Medical University | Not yet recruiting --> Recruiting
    Enrollment open
    |
    YSCH-01
    over2years
    YSCH-01: Safety and Tolerability Study of Recombinant L-IFN Adenovirus Injection in Patients With Recurrent Glioblastoma (clinicaltrials.gov)
    P1, N=6, Not yet recruiting, Binhai Hospital of Fujian Medical University
    New P1 trial
    |
    YSCH-01